Early‐stage vocal cord cancer treated with hypofractionated radiotherapy to the larynx with or without concurrent chemotherapy

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>We report outcomes among patients with T2 and select T3 glottic squamous cell carcinoma (SCC) treated with radiotherapy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We reviewed T2 and T3 (only paraglottic space invasion) N0 M0 glottic SCC patients treated with curative‐intent hypofractionated larynx radiotherapy, with or without concurrent systemic therapy.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 71 patients, those who received concurrent chemotherapy (23/71; 32%) had worse prognostic factors, including impaired cord mobility (70% vs. 40%, <jats:italic>p</jats:italic> = 0.02) and larger median gross tumor volume (3.0 vs. 1.6 cm<jats:sup>3</jats:sup>, <jats:italic>p</jats:italic> = 0.003). Over a median follow‐up of 3.8 years, 2‐year local control among patients with impaired cord mobility appeared higher for those who received chemotherapy (88% vs. 61%, <jats:italic>p</jats:italic> = 0.12), but the difference was not statistically significant. Acute and late toxicity rates were not higher among patients who received chemotherapy.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The addition of concurrent platinum‐based chemotherapy to hypofractionated larynx radiotherapy among patients with early‐stage glottic SCC with impaired cord mobility appears safe and worthy of additional investigation.</jats:p></jats:sec>